Proton magnetic resonance spectroscopy detects cerebral metabolic derangement in a mouse model of brain coenzyme a deficiency

Yanan Li, Jeffrey Steinberg, Zane Coleman, Shubo Wang, Chitra Subramanian, Yimei Li, Zoltán Patay, Walter J. Akers, Charles O. Rock, Suzanne Jackowski, Puneet BaggaJournal of Translational Medicine 2022 · DOI

TL;DR

This study utilizes proton magnetic resonance spectroscopy (¹H MRS) to non-invasively monitor brain metabolic changes in a mouse model of Pantothenate Kinase-Associated Neurodegeneration (PKAN), a rare and devastating neurological disorder. They demonstrate that ¹H MRS can effectively detect metabolic derangements and, crucially, track the therapeutic response of a novel drug candidate, BBP-671, by observing the restoration of key metabolites like glutamate/glutamine.

What Problem Does This Paper Address?

Pantothenate Kinase-Associated Neurodegeneration (PKAN) is a severe, life-threatening neurological disorder characterized by movement disorders and iron deposition in the brain. It's caused by mutations in the PANK2 gene, leading to a deficiency in Coenzyme A (CoA) biosynthesis. CoA is a vital cofactor for numerous metabolic processes, including energy production via the tricarboxylic acid (TCA) cycle, fatty acid metabolism, and neurotransmitter synthesis. Despite the clear link between CoA deficiency and PKAN, there's a significant unmet need for reliable methods to diagnose the condition, monitor disease progression, and, most importantly, track the effectiveness of potential therapeutic interventions. Current diagnostic methods are limited, and there are no approved treatments for PKAN. This paper addresses this gap by exploring ¹H MRS as a non-invasive tool to identify and quantify these metabolic disturbances and to assess therapeutic efficacy in a preclinical model.

Methods

The researchers employed proton magnetic resonance spectroscopy (¹H MRS), a well-established non-invasive neuroimaging technique, to analyze brain metabolite levels in vivo. Specifically, they used a Bruker Clinscan 7T MRI scanner with a mouse brain surface receive coil. The ¹H MRS acquisition involved a PRESS sequence with a repetition time/echo time of 3000/11 ms, acquiring 128 averages over a total scan time of 21 minutes. A 3.5×4.5×2.0 mm³ voxel was positioned in the midbrain to cover the thalamus and hippocampus.

Data processing was performed using LCModel software, a standard tool for ¹H MRS analysis, which employs a least-squares fitting approach. Metabolite concentrations were reported as ratios to total creatine (tCr), a common practice to account for variations in tissue volume and magnetic field. Statistical analysis involved Wilcoxon Rank sum tests with Bonferroni correction to compare metabolite ratios between different experimental groups.

Datasets

The study utilized a neuronal Pank1 and Pank2 double-knockout (SynCre⁺ Pank1,2 dKO) mouse model of brain CoA deficiency. This model was compared against wild-type littermate controls. The treatment group received a novel Pantazine compound, BBP-671, administered via fortified chow. No new benchmarks or datasets were introduced; the focus was on applying existing techniques to a specific disease model.

Key Insights and Ideas

  • ¹H MRS as a sensitive biomarker for CoA deficiency: The study successfully demonstrated that ¹H MRS can detect significant alterations in key brain metabolites (glutamate/glutamine, N-acetyl aspartate, and lactate) in a mouse model of CoA deficiency, directly linking these changes to the genetic disruption of Pank1 and Pank2.
  • Glutamate/Glutamine (Glx) as a promising therapeutic response marker: The most striking finding was the complete restoration of Glx levels in the brains of mice treated with BBP-671. This suggests that Glx is a highly sensitive and clinically translatable biomarker for assessing therapeutic efficacy in PKAN.
  • NAA and Lactate as potential secondary biomarkers: While Glx showed the most robust recovery, NAA and lactate also trended towards improvement with treatment, indicating their potential as complementary biomarkers, though requiring further investigation.
  • BBP-671's mechanism of action: The study highlights that BBP-671, a Pantazine, allosterically activates the PANK3 isoform, leading to increased CoA production and subsequent restoration of TCA cycle metabolism and neurotransmitter synthesis.
  • Mouse model limitations: The authors acknowledge that the Pank1,2 dKO mouse model, while valuable, may not fully recapitulate all aspects of human PKAN, particularly the iron accumulation observed in the basal ganglia and potential white matter pathology.

Key Results

  • Metabolic Derangements in dKO mice: SynCre⁺ Pank1,2 dKO mice exhibited significantly reduced ratios of Glx/tCr, NAA/tCr, and lactate/tCr compared to wild-type controls.
  • Therapeutic Efficacy of BBP-671: Treatment with BBP-671 completely restored glutamate/glutamine (Glx) levels in the dKO mice.
  • NAA/tCr and Lactate/tCr trends: The NAA/tCr ratio showed a trend towards improvement with BBP-671 treatment, though not statistically significant. Similarly, the lactate/tCr ratio also trended towards improvement.
  • Improved Lifespan and Locomotion: In a separate study, BBP-671 treatment led to improved lifespan, weight gain, and locomotion in the dKO mice, mirroring previous findings with other Pantazine compounds.

Limitations and Future Work

The authors acknowledge several limitations:

  • Model Specificity: The Pank1,2 dKO mouse model primarily reflects metabolic changes in gray matter and does not exhibit the iron accumulation characteristic of human PKAN.
  • White Matter Pathology: Mouse models are less effective for studying white matter pathologies, which are observed in human PKAN patients.
  • Clinical Translation: While promising, the study was conducted in a preclinical model, and further validation in human PKAN patients is necessary.

Future work should focus on:

  • Further validation of Glx as a biomarker: Investigating Glx dynamics in larger cohorts and across different stages of the disease.
  • Exploring other metabolites: Deeper investigation into the roles of NAA and lactate as potential biomarkers.
  • Developing therapies targeting iron accumulation: Addressing the iron deposition aspect of PKAN, which is not recapitulated in this model.
  • Clinical trials: Translating these findings into human clinical trials to evaluate the efficacy and safety of BBP-671 and other Pantazine-based therapies.

Summary updated

Abstract

BBP-671 treatment completely restored glutamate/glutamine levels in the brains of the mouse model, suggesting that these metabolites are promising clinically translatable biomarkers for future therapeutic trials.
BibTeX
@article{li2022proton,
  author = {Yanan Li and Jeffrey Steinberg and Zane Coleman and Shubo Wang and Chitra Subramanian and Yimei Li and Zoltán Patay and Walter J. Akers and Charles O. Rock and Suzanne Jackowski and Puneet Bagga},
  title = {{Proton magnetic resonance spectroscopy detects cerebral metabolic derangement in a mouse model of brain coenzyme a deficiency}},
  journal = {Journal of Translational Medicine},
  year = {2022},
  doi = {10.1186/s12967-022-03304-y},
}
Figure